Compare ITG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITG | IRWD |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.3M | 713.8M |
| IPO Year | 2026 | 2009 |
| Metric | ITG | IRWD |
|---|---|---|
| Price | $12.35 | $4.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 128.4K | ★ 1.4M |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $7.42 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $10.37 | $1.26 |
| 52 Week High | $16.00 | $5.78 |
| Indicator | ITG | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 49.67 |
| Support Level | $12.07 | $3.89 |
| Resistance Level | $13.91 | $4.52 |
| Average True Range (ATR) | 0.84 | 0.16 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 53.88 | 42.59 |
ITG Inc provides services to the digital and other utility infrastructure industries throughout the United States. Its services support the planning, design, construction, operation, maintenance, and expansion of broadband and other infrastructure networks. It operates through two complementary service lines: i) Engineering & Maintenance: It provides re-occurring, mission-critical services required by network owners to operate, maintain, optimize and expand their infrastructure. ii) Infrastructure Deployment. It provides large-scale network and fiber construction services for incumbent carriers, overbuilders, and data center operators and underground civil construction services for public and private utilities. The majority of revenue is derived from the Engineering & Maintenance services.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.